According to a recent LinkedIn post from RECEPTORAI, CEO and founder Dr. Alan Nafiev recently spoke at the Drug Discovery Chemistry conference in San Diego about the firm’s work on peptide drug design. The presentation, as described in the post, focused on how Receptor.AI’s approach seeks to simultaneously improve affinity and permeability for a 16‑mer peptide.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post indicates that the company’s methods target the design of membrane‑ and GI‑permeable peptides by modeling chameleonic features, permeability‑relevant conformations, and membrane‑associated behavior in different environments. For investors, this suggests ReceptorAI is positioning its platform toward complex peptide therapeutics, potentially enhancing its value proposition in AI‑driven drug discovery collaborations.
By highlighting participation at a specialized chemistry conference, the post also points to ongoing engagement with scientific and industry peers at the intersection of AI and computational chemistry. Such visibility could support future partnering, licensing, or service agreements, which may be important drivers of commercial traction for a private, platform‑oriented company like RECEPTORAI.